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Synthesis of a new methoxy dibenzofluorene through alkylation, cyclodehydration and
aromatization in a one-pot operation is achieved for the first time. Using this hydrocarbon, a
few derivatives are prepared through aromatic nitration, catalytic hydrogenation, coupling
reaction with a side chain and reduction. The benzylic position of this hydrocarbon with
the side chain is oxidized and reduced. Some of these derivatives have demonstrated
excellent antitumor activities in vitro. This study confirms antitumor activity depends on
the structures of the molecules.
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INTRODUCTION
Polyaromatic compounds are prepared by numerous methods
(Clar, 1964; Harvey, 1997). Some of the methods are widely
used in the synthesis of compounds containing multiple ring
containing structures all of which are not aromatic. Numerous
polyaromatic compounds have demonstrated carcinogenic and
mutagenic activities. The causes of these adverse activities of
these compounds have been realized through different hypo-
thetical mechanisms and theories (Di Raddo and Chan, 1982).
Most of the past research on polyaromatic compounds is mainly
based upon two important areas: synthesis and carcinogenic-
ity/mutagenicity. A few suitably substituted polycyclic aromatic
compounds have demonstrated anticancer activities, but their
mechanism of action is not established. For example, the anti-
cancer activity of these compounds may be due to their inter-
calating properties or covalent binding abilities to DNA (Palmer
et al., 1988; Denny et al., 1990). In addition, cell membrane inter-
action of these compounds is also proposed as their mechanism
of actions. Our study has indicated that substituted chrysenes act
on the cancer cell through interactions with the cell membrane
(Becker and Banik, 1998).
Since some polyaromatic compounds have demonstrated car-
cinogenic and mutagenic properties, the development of such
compounds as antitumor drugs may raise concerns. However,
many clinically active anticancer drugs that are not derived from
polyaromatic compounds are carcinogenic and other harmful
properties. Benzene is highly carcinogenic, but many compounds
derived from benzene are life-saving drugs. It has been shown that
alteration of the structure of polyaromatic compounds can help to
interact with specific organelles to evoke selective cytotoxic reac-
tions (Palmer et al., 1992; Cherubim et al., 1993). This simple,
but very crucial concept is used by many scientists and as result
of these approaches many carbazoles, anthracenes, and related
structures are in current clinical use (Iyengar et al., 1997; Brana
et al., 2001; Martinez and Chacon-Garcia, 2005; Landis-Piwowar
et al., 2006; Rescifina et al., 2006; Bandyopadhyay et al., 2012).
Despite huge progress in the identification of numerous active
cancer chemotherapeutic agents, synthesis and biological evalu-
ation of new methoxy dibenzofluorene derivatives has not been
reported. The skeleton present in this molecule is highly suited
for several structural alterations. The pentacyclic aromatic rings
may also interact with cell membranes as we have observed in our
study with chrysene derivatives. Moreover, the 13-position of this
type of ring system is available for substitution. The active CH2
group present in the 13-position may create cation, anion and
radical. Thus, it would be highly important to study the effects
of functionalized methoxy dibenzofluorenes as new anticancer
agents (Becker et al., 2000). We report herein our preliminary
findings that uncover anticancer activities that depend on the
groups present in these molecules.
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RESULTS AND DISCUSSIONS
The reaction of 2-methoxy β-tetralone (1) with β-methyl naph-
thalenyl bromide (2) in the presence of sodium hydride in ben-
zene at −10◦C for 1 h and treatment of the resulting intermediate
with methane sulfonic acid for additional 3 hours afforded 2-
methoxy dibenzo[a,g]fluorene (3) in 40% yield in a one-pot
operation (Scheme 1). This method is very simple since alky-
lation, cyclodehydration and aromatization take place simulta-
neously. This method demonstrates a powerful strategy for the
preparation of methoxy dibenzo[a,g]fluorene.
In another method, compound 1 was converted to enam-
ine, alkylated the enamine with 2 and the intermediate was then
cyclized and aromatized to 3 (Scheme 1). The yield of the product
3 obtained by these two methods was comparable.
Our plan was to add a linker with 4-carbon chain that have
a basic nitrogen unit at the terminal site to any carbon at 3 and
oxidize the benzylic methylene group. However, the plan was not
straight forward. Oxidation of 3 to benzylic ketone 4 by sodium
bismuthate was achieved (Scheme 2). However, ketone 4 failed
to produce nitro compounds under different reaction conditions
with nitric acid and metal salts (Samajdar et al., 2000; Bose et al.,
2007). The keto group deactivated the aromatic ring systems sig-
nificantly and as a results no nitration of the aromatic ring was
possible.
Functionalization of monocyclic and bicyclic aromatic com-
pound through electrophilic nitration is explored by many meth-
ods. The failure of compound 4 to undergo nitration appears to
be the result of deactivation exerted by the keto group present in
the bridged system of the ring. On the basis of the deactivation
hypothesis, we performed nitration of the hydrocarbon 3 with
nitric acid/sulfuric acid mixture and by bismuth nitrate-induced
clay impregnated reactions.
The reaction was successful and the product was a single
nitro derivative 5 obtained in excellent yield. The position of the
nitro group in the aromatic ring was assigned by NMR spec-
tra and comparison with our previous compounds that have no
methoxy groups. It was important to note that nitration takes
place at the unsubstituted aromatic ring. Several methods were
attempted to reduce the nitro group in 5. Thus reduction of 5
with hydrogen gas/Pd-C, hydrazine/Pd-C, samarium/iodine, and
indium/ammonium chloride were effective in producing the cor-
responding amino compound 6. The amine 6 was then reacted
with the acids described earlier in the presence of isobutylchlo-
roformate and triethylamine (Becker and Banik, 1998). The
diamides 7a (X=CH2) and 7b (X=NCH3) were obtained in 70%
yield. On oxidation, the methylene group in 7 produced the
ketone 9. The ketone 9 was reduced to the alcohol 10. Diborane
was used to reduce the amide groups in 7 to 8 (Schemes 3 and 4).
These compounds were tested in the University of Texas M.
D. Anderson Cancer Center’s Core Analytical Laboratory against
eight tumor lines all of which have been used in the NCI panel
for the testing of chemotherapeutic agents. The antitumor activity
Scheme 2 | Oxidation and nitration study of methoxy dibenzofluorene.
Scheme 1 | Synthesis of methoxy dibenzofluorene.
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Scheme 3 | Synthesis of methoxy dibenzofluorene derivatives with amine side chain.
Scheme 4 | Synthesis of methoxy dibenzofluorene derivatives with amide side chain.
of these new methoxy diben-zofluorene derivatives 7 to 10 were
performed and compared with cisplatin (Table 1). The results of
these tests are interesting, and indicate the significance of alter-
ing structures in terms of antitumor activities. Compounds 7b,
8a and 8b were more active than cisplatin in many of these cancer
cell lines.
In fact, 7b, 8a, and 8b are some of the most active molecules
that we have derived from the study of polyaromatic compounds.
The keto group at position 13 created the fluorenone 9 with
reduced activity. It was clear that the piperidine group at the ter-
minus of the alkyl chain decreases activity compared with those
that terminate with the N-methyl piperazine. Clearly, this was
observed in compounds 9 and 10. The alcohol group at position
13 in compound 10b produced a reduced activity when com-
pared with 7b. Reduction of 7 resulted in their amine derivative 8.
An impressive increase was seen in the amine derivatives 8a and
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Table 1 | IC50 (micro molar) of compounds 7 to 10 MTT assay (72h continuous exposure)a.
Cell lines Cisplatin 7a 7b 9a 9b 10a 10b 8a 8b
B-16 7.33 128.50 4.30 >100 12.30 28.70 11.08 4.05 1.67
BRO 5.66 103.54 3.89 >100 12.67 31.74 12.41 4.26 3.54
HL-60 - 33.33 3.48 74.18 7.33 12.00 4.19 - -
L-1210 - 53.70 3.98 78.36 25.85 16.44 7.05 - -
MCF-7 15.99 50.63 4.32 78.30 13.70 20.11 11.85 4.82 4.56
OVCAR-3 - 94.32 4.11 98.00 2.61 19.77 8.66 3.12 1.80
PC-3 1.66 32.52 3.78 31.45 27.32 13.88 6.56 4.49 4.39
HT-29 15.99 >100 3.86 61.31 21.66 9.98 13.67 4.11 3.27
aAll data were provided as IC50 values (micro molar) and assays were conducted by 72 h continuous exposure by the MTT method. The final concentration of
solvent was <0.625% which was not toxic to the cells. All dilutions were made in RPMI 1640 with 10% FBS. The cytotoxity data is based on at least three separate
experiments with deviations within 0.2µmol.
8b regardless of the terminus units. The cause of the spectacu-
lar differences of the activity of the two series of compounds in
all cell lines is not known. A similar observation was noted with
demethoxy analogs of the dibenzofluorene and chrysene deriva-
tives. Amino compounds were more potent than amides in these
two series of molecules. This was confirmed by the fact that com-
pounds 8a, 8b and 7b are the more cytotoxic compared to 7a. A
slight increase in activity in 10b compared to 10a and 9b com-
pared to 9a was also observed. The introduction of at one basic
group (tertiary amine) at the terminal site of these molecules was
probably responsible for the increased activity. The basic units
will help to increase the pKa value so that these molecules can
be protonated at physiological pH. These type of polyaromatic
highly lipophilic and cationic molecules are expected to bind to
several anionic structures inside cells such as to phosphate groups
of nucleic acids (DNA and RNA). These lipophilic molecules are
also expected to interact strongly with the lipids components in
cell membrane. The in vitro cytotoxicity of these new molecules
are similar or better than that of cisplatin which act through a
different mechanism of action primarily through cell damage and
death. However, it is also known that activity in vitro is not pro-
portional to clinical applications in many instances. For example,
adriamycin is one of the most potent anticancer drugs in vitro and
in vivo, but it is also established that it is not a successful clinically
active agent.
Notably, the aromatic methoxy group present in the molecules
as described herein can be used for a detail structure-activity
relationships study. For example, the aromatic methoxy group
can be converted to a phenolic hydroxyl group and phenolic
hydroxyl group can be alkylated or acylated with different types
of side chains. In addition the phenolic hydroxyl group can be
further used to perform a number of electrophilic substitution
(halogenation, nitration and sulfonation).
EXPERIMENTAL (GENERAL METHODS)
All reactions described in this paper were carried out under a
well-ventilated hood. Dichloromethane and tetrahydrofuran were
dried and freshly distilled before use. IR spectra were recorded on
a Perkin Elmer instrument and UV spectra were recorded on a
Perkin Elmer instrument. NMR spectra were recorded on Bruker
200 and 300MHz spectrometers. Chemical shifts were recorded as
delta values in parts permillion downfield from tetramethyl silane
as the internal standard in CDCl3. Mass spectra were obtained on
aMicromass VG platformwith a single quadrapole and fitted with
an electrospray source. Elemental analyses were performed by
Schwarzkopf Microanalytical Laboratory, Inc., New York. Melting
points were taken in open capillary tube. Column chromatogra-
phy was carried out with Aldrich silica gel (230 mesh). TLC was
run with pre-coated silica gel plate. Sodium sulfate was used as
the drying agent after all extractions.
2-METHOXY-13/H-DIBENZOFLUORENE (3)
Sodium hydride (10 g) in dry benzene (30mL) was taken in a
flask and it was cooled at 0◦ to −10◦C. 2-Methoxy β-tetralone
1 (5 g) dissolved in dry benzene (25mL) was added to it in an
inert atmosphere and the reaction mixture was stirred for 30min.
β-Methyl naphthalenyl bromide (2, 1.5 equivalent with respect to
ketone) in benzene was added to the enolate at cold conditions
and the reaction mixture was stirred at 0◦C for additional 1 h.
Methane sulfonic acid (20mL) was added carefully to the reac-
tion mixture and it was then refluxed for 3 h. Water (50mL) was
added to the reaction mixture and benzene layer was collected.
The organic part was washed with aqueous NaOH solution (2%,
25mL) and dried. On evaporation of the solvent, hydrocarbon 3
was obtained in 40% yield. This was used directly for the next step
without purification.
2-METHOXY-11-NITRO-13/H-DIBENZOFLUORENE (5)
To an ice-cold solution of the hydrocarbon 3 (500mg) in THF
(20mL) was added glacial acetic acid (25mL). Nitric acid (90%,
10mL) was added drop wise to the solution at ice-cold tempera-
ture. After the addition was complete, stirring was continued for
additional 2 h at room temperature. The reaction mixture was
then poured into crushed ice, filtered, and washed with water
until free from acid. The crude product 5 (80%) was used directly
for the next step.
2-METHOXY-11-AMINO-13/H-DIBENZOFLUORENE (6)
Nitro compound 5 (400mg) was hydrogenated with 10% Pd/C
(50mg) in ethanol for 24 h to afford the amine 6 (90%); IR
(CH2Cl2): 3430, 3355, 3050, 2955, 2920, 2838, 1695, 1618, 1585,
1510, 1440 cm−1; 1H NMR (200MHz): δ 8.80–8.76 (1H, d),
8.40–8.34 (1H, d), 8.10–7.80 (3H, m), 7.69–7.43 (3H, m), 7.15
(1H, s), 7.02 (1H, s), 4.18 (2H, s), 3.72 (s, 3H); 13C NMR
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(400MHz): δ142.5, 142.0, 140.7, 140.0, 139.0, 131.2, 130.2, 128.7,
127.3, 126.4, 126.1, 125.2, 124.3, 124.1, 124.0, 123.5, 123.3, 121.7,
120.8, 107.7, 37.4; 30.05; Mass: 312 (M+H)+.
2-METHOXY-N-[2/-(13/H-DIBENZO[A,G]-FLUORENYL)]-4-(1/-
PIPERIDINYL)-BUTANE-1,4-DICARBOXIAMIDE (7a)
To an ice-cold solution of the acid described in Scheme 3 (1.0 g)
in dry CH2Cl2 (50mL) was added dry triethylamine (0.8mL)
followed by freshly distilled isobutyl chloroformate (0.6mL).
Stirring was continued in cold conditions for 10min. Next this
mixed anhydride was added drop wise to an ice-cold solution
of the amine 6 (700mg) in dry CH2Cl2 (50mL) and stirring
was continued overnight. The reaction mixture was washed suc-
cessively with HCl (5%), NaHCO3(5%), brine and then dried.
Removal of the solvent under reduced pressure afforded the
crude product, which was purified by column chromatography
over silica gel to obtain 7a (70%); mp 180–181◦C; IR (CH2Cl2):
3260, 2956, 1650, 1540, 1500, 1452, 1279, 80, 735 cm−1; 1HNMR
(200MHz): δ 9.42 (1H, s, ArNHCO-), 8.86 (J = 8.42Hz, 1H,
d, Ar), 8.47 (J = 8.68Hz, 1H, d, Ar), 8.39 (1H, s, Ar), 8.15
(J = 8.35Hz, 1H, d, Ar), 8.05 (J = 8.03Hz, 1H, d, Ar), 7.95
(J = 9.29Hz, 2H, d, Ar), 7.60–7.40 (2H, m, Ar), 7. 35 (1H, s, Ar),
4.30 (2H, s, benzylic CH2), 3.81 (3H, s, OCH3), 3.75–3.60 (2H,
brt, -CONCH2), 3.55–3.36 (2H, brt,-CONCH2), 3.04–2.74 (4H,
m, -COCH2CH2CO-), 1.80–1.42 (6H, brs, -NCH2(CH2)3CH2-);
13C NMR: δ 171.9, 169.2, 140.2, 138.9, 138.6, 137.9, 133.5, 130.8,
129.9, 129. 6, 128.5, 126.8, 126. 2, 125.4, 125.0, 124.8, 124.3, 124.0,
123.2, 121.4, 121.0, 116.4, 45.5, 43.4, 42.1, 36.0, 32.4, 28.9, 25.4,
24.8, 23.3; Mass: 479 (M+H)+; Anal. calcd for C31H30N2O3:




70%; mp 208–210◦C; IR (neat): 3260, 2925, 1642, 1538, 1441,
1290, 1258, 1145, 809, 745 cm−1; 1H NMR (200MHz): δ 9.12
(1H, s, ArNHCO-), 8.80 (J = 8.40Hz, 1H, d, H7), 8.45 (J =
8.70Hz, 1H, d, Ar), 8. 42 (1H, Ar), 8.29 (1H, s, Ar), 8.10
(J = 8.32Hz, 1H, d, Ar), 8.05 (J = 8.03Hz, 1H, d, Ar), 7.94 (J =
8.00Hz, 2H, d, Ar), 7.71–7.37 (3H, m, Ar), 4.22 (2H, s, benzylic
CH2), 3.90 (3H, s), 3.81–3.64 (2H, brt, -CONCH2), 3.60–3.46
(2H, brt, -CON-CH2), 3.00–2.74 (4H, m,-COCH2CH2CO-),
2.54–2.20 (6H, m, -(CH2)2NCH3, with a singlet at δ 2.32 for -
NCH3); 13C NMR (300MHz): δ 171.1, 169.5, 142.0, 140.8, 139.5,
134.2, 132.7, 131.6, 129.4, 128.8, 128.4, 127.3, 126.2, 125.9, 125.1,
124.8, 124.7, 124.6, 124.0, 122.2, 121.4, 117.6, 54.7, 54.3, 46.0,
45.3, 42.4, 42.1, 36.1, 32.9, 29.3; Mass (M+H)+: 494; Anal. calcd
for C31H31N3O3: C, 75.45; H, 6.28; N, 8.51%. Found: C, 75.48;
H, 6.05; N, 8.43%.
2-METHOXY-N-[2/-(13/H-DIBENZO[A,G]-FLUORENE-13/-ONE]-4-(1/-
PIPERIDINYL)-BUTANE-1,4-DICARBOXIAMIDE (9a)
To a solution of 7a (650mg) in dry THF (40mL) at −78◦C
under argon was added a solution of n-BuLi (1.6mL, 2.5M)
in cyclohexane. The deep-yellow colored solution was stirred
for 2 h at this temperature. Dry O2 was bubbled through the
solution for 1 h. The temperature was allowed to rise to room
temperature while O2 continued to bubble through the solution
for an additional 3 h. The reaction was quenched with water
(20mL) and CH2Cl2 (20mL), and stirring was continued for
30min. The organic layer was collected, washed with brine, and
dried. On evaporation of the solvent, the crude product was
obtained, which was crystallized from CH2Cl2/hexanes to yield
9a (60%); mp 220–222◦C; IR (neat): 3240, 2936, 1700, 1645,
1520, 1450, 1264, 810, 802, 732, 702 cm−1; 1H NMR (200MHz):
δ 9.45 (1H, s, ArNHCO-), 8.91 (J = 8.40Hz, 1H, d, Ar), 8.48–
8.45 (1H, m, Ar), 8.20–8.05 (2H, m, Ar), 7.88 (J = 8.45Hz, 1H,
d, Ar), 7.72 (J = 8.18Hz, 1H, d, Ar), 7.56–7.44 (2H, m, Ar),
7.35 (J = 8.06Hz, 1H, d, Ar), 3.80–3.62 (2H, brt, -CONCH2),
3. 78 (3H, s, OCH3), 3.60–3.37 (2H, brt, -CONCH2), 2.85 (4H,
s,-COCH2CH2CO-), 1.77–1.48 (6H, brs, -NCH2(CH2)3CH2-);
13C NMR (300 MHz, CDCl3): δ 194.8, 170.8, 170.2, 147.0, 140.2.
138.1, 135.2, 133.9, 132.5, 131.0, 130.8, 129.2, 128.3, 128.0, 127.2,
127.1, 126. 4, 126.1, 125.2, 124.8, 123.8, 123.2, 119.9, 115.0, 46.5,
44.7, 26.5, 26.2, 24.2, 22.1, 14.3; Mass (M+H)+: 493; Anal. calcd
for C31H28N2O4: C, 75.60; H, 5.69; N, 5.69%. Found: C, 75.51;
H, 5.62; N, 5.54%.
2-METHOXY-N-[2/-(13/H-DIBENZO[A,G]-FLUORENE-13/-ONE]-4-(4/N-
METHYL-PIPERAZINYL)-BUTANE-1,4-DICARBOXIAMIDE (9b)
60%; mp 210–211◦C; IR (neat): 3235, 2925, 2850, 1700, 1648,
1545, 1520, 1460, 1268, 1258, 1000, 810, 752, 704 cm−1; 1H
NMR (200MHz): δ 9.15 (1H, s, ArNHCO-), 8.94 (J = 8.57Hz,
1H, d, Ar), 8.48–8.35 (1H, m, Ar), 8.33–7.87 (2H, m, Ar), 7.82
(J = 8.54Hz, 1H, d, Ar), 7.70 (J = 8.33Hz, 1H, d, Ar), 7.58–7.40
(3H, m, Ar), 7.40 (J = 7.82Hz, 1H, d, Ar), 3.82–3.38 (4H, m,
CON(CH2)2, 3.77 (s, 3H), 2.95 (4H, s, -COCH2CH2CO-), 2.61–
2.19 (7H, m, (-CH2)2NCH3 with a singlet at δ 2.34 for-NCH3);
13C NMR (300MHz): δ 196.0, 171.2, 171.0, 146.8, 138.2, 135.2,
135.8, 134.1, 133.8, 132.5, 130.7, 129.6, 128.4, 128.2, 128.0, 127.5,
126.6, 126.2, 124.5, 124.1, 123.4, 120.9, 114.4, 54.9, 54.2, 48.9,
45.9, 45.3, 32.6, 23.1, 14.3; Mass (M+H)+: 508; Anal. calcd for




To a solution of 9a (200mg) in absolute EtOH (20mL) was
added NaBH4 (50mg) at ice-cold temperature and the solution
was stirred under this condition for 30min. The temperature
was allowed to rise to room temperature, and stirring was con-
tinued for an additional 4 h. The reaction was quenched by
addition of water (10mL) and the reactants were extracted with
CH2Cl2 (50mL), washed with brine and dried. On removal of
the solvent, crude product was crystallized from CH2Cl2/hexanes
to yield 140mg (90%) of pure 10a; mp 225–228; IR (neat):
3440, 3260, 2940, 2860, 1650, 1625, 1540, 1446, 1270, 1260,
1170, 1090, 810, 750 cm−1; 1H NMR (200MHz): δ 9.25 (1H, s,
ArNHCO-), 8.70 (J = 8.62Hz, 1H, d, Ar), 8.39 (J = 8.07Hz, 1H,
d, Ar), 8.18–8.12 (2H, m, Ar), 8.05–7.85 (2H, m, Ar), 7.58–7.22
(4H, m, Ar), 5.85 (J = 10.28Hz, 1H, d), 3.80 (3H, s, OCH3),
3.78–3.52 (2H, brt, -CONCH2), 3.50–3.38 (2H, brt,-CONCH2),
3.05–2.66 [5H, m, -COCH2CH2CO- with a doublet at δ 2.75
(J = 10.28Hz which disappeared with D2O)], 1.75–1.42 [6H,
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brs, -NCH2(CH2)3CH2-]; Mass (M+H)+: 495; Anal. calcd for




90%; mp 175–177◦C; IR (neat): 3450, 3265, 2800, 1630, 1545,
1502, 1442, 1300, 1295, 1252, 1190, 1132, 1005, 818, 755 cm−1;
1H NMR (200MHz): δ 9.10 (1H, s, ArNHCO-), 8.56 (J =
8.48Hz, 1H, d, Ar), 8.39 (J = 8.26Hz, 1H, d, Ar), 8.29
(J = 8.14Hz, 1H, d, Ar), 8.15 (1H, s), 8.11–7.76 (2H, m, Ar),
7.60–7.4 (4H, m, Ar), 5.81 (1H, s), 3.80 (3H, s), 3.75–3.22 (4H,
m, -CON(CH2)2-), 2.82-2.55 (4H,m,-COCH2CH2CO-), 2.73 (d,
IH, disappeared with D2O, 2.38-2.12(7H,m, (-CH2)2NCH3, with
a singlet at δ 2.11 for -NCH3); Mass (M+H)+: 510; Anal. calcd
for C31H31N3O4: C, 73.08; H, 6.09; N, 8.25%. Found: C, 73.10;
H, 6.11; N, 8.08%.
2-METHOXY-N-[2/-(13/H-DIBENZO[A,G]-FLUORENYL]-4-(10-
PIPERIDINYL)-BUTANE-1,4-DIAMINE (8a)
To a solution of 7a (50mg) in THF (50mL) were added borane-
methyl sulfide complex (70mL, 5 M) solution in diethyl ether
under argon at ice-cold temperature, and the mixture was
refluxed for 16 h. Then, HCl (15mL, 5%) was added, and the
mixture was refluxed for another 10 h. The solution was cooled,
added to 1M sodium hydroxide solution, extracted with ethyl
acetate, washed with brine, and dried. On removal of the solvent,
the crude diamine solidified, which was crystallized from ethyl
acetate: hexanes (20:80) to give the pure diamine 8a (80%); mp
170–171◦C; IR (neat): 3385, 2939, 2755, 1630, 1620, 1581, 1560,
1545, 1468, 1453, 1348, 1278, 1178, 1110, 1050, 800, 770 cm−1;
1H NMR (200MHz): δ 8.85 (J = 8.11Hz, 1H, d), 8.39 (J =
8.70Hz, 1H, d), 8.14–7.90 (3H, m, Ar), 7.66–7.30 (4H, m, Ar),
6.95 (1H, s), 4.28 (2H, s), 3.82 (3H, s), 3.48 (J = 6.60Hz, 2H,
t, ArNHCH2-), 2.66–2.35 [6H, brt, H2C-N(CH2)2-], 1.96–1.40
(10H, m); 13C NMR (300 MHz): δ 145.0, 143.3, 141.4, 138.8,
137.5, 130.6, 130.1, 129.1, 128.8, 128.1, 126.2, 125.9, 125.2, 124.6,
124.2, 124.0, 123.9, 122.1, 121.7, 120.9, 101.4, 58.2, 54.5, 50.2,
48.3, 44.1, 37.4, 27.1, 26.1, 24.4, 24.2; Mass (M+H)+: 451; Anal.
calcd for C31H34N2O: C, 82.66; H, 7.55; N, 6.22%. Found: C,
82.50; H, 7.41; N, 6.13%.
2-METHOXY-N-[2/-(13/H-DIBENZO[A,G]-FLUORENYL)]-4-(4/N-
METHYLPIPERAZINYL)-BUTANE-1,4-DIAMINE (8b)
80%; mp 155–157◦C; IR (neat): 3400, 2930, 2850, 1622, 1590,
1565, 1508, 1410, 1348, 1246, 1155, 1018, 810, 745 cm−1; 1H
NMR (200MHz): δ 8.85 (J = 8.35Hz, 1H, d), 8.39 (J = 8.70Hz,
1H, d), 8.10–7.86 (4H, m, Ar), 7.76–7.28 (4H, m, Ar), 6.98
(1H, s), 4.28 (2H, s), 3.78 (3H, s), 3.40 (J = 6.60Hz, 2H, t,
ArNHCH2-), 2.71–2.35 [10H, brt, (5-NCH2)], 2.32 (3H, s), 1.99–
1.58 (4H, m); 13CNMR (300 MHz): δ 144.1, 142.9, 141.4, 139.1,
131.2, 131.0, 130.1, 129.8, 128.4, 127.0, 126.6, 126.2, 124.8, 123.9,
123.3, 122.8, 122.3, 121.1, 120.9, 101.4, 55.1, 54.7, 53.2, 48.8, 46.1,
44.4, 40.2, 36.9, 29.9, 28.1, 24.8132; Mass (M+H)+: 466; Anal.
calcd for C31H35N3O: C, 80.17; H, 7.32; N, 9.05%. Found: C,
80.04; H, 7.45; N, 9.14%.
CONCLUSION
Despite significant progress in the identification of novel can-
cer chemotherapeutic agents, synthesis and biological evaluation
of new methoxy dibenzofuorene derivatives is not known. The
synthesis of this aromatic hydrocarbon through one-pot method
may receive well attention.We have demonstrated an electrophilic
nitration of 2-methoxy-13H-dibenzo[a,g]-fluorene for the first
time. Despite a complex structure and number of available sites,
regioselective nitration of methoxy dibenzofluorene is interest-
ing. The crucial antitumor activity of the several new compounds
against a number of cancer cell lines is promising and this will
open up a possibility of conducting a more detail structure-
activity relationship study of other analogues that will be derived
through chemical manipulation.
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